```html

Loa loa infection (Loiasis) – Comprehensive Medical Guide

Overview

Loa loa is a parasitic filarial worm that causes the disease known as loiasis or “African eye worm.” The adult worm lives in the sub‑cutaneous tissue of humans and migrates through the skin, occasionally crossing the conjunctiva of the eye, which gives the disease its common name.

Loiasis is endemic to the rain‑forests and savannahs of West and Central Africa, particularly in:

• Cameroon
• Republic of the Congo
• Democratic Republic of the Congo
• Equatorial Guinea
• Gabon
• Central African Republic
• South‑Western Nigeria

According to the World Health Organization (WHO), an estimated 10–13 million people are infected worldwide, with the majority living in the countries listed above. The disease primarily affects adults who spend many hours outdoors—farmers, hunters, and forest workers—because transmission depends on the bite of infected Chrysops (deer‑fly) vectors.

Symptoms

Many infected individuals remain asymptomatic for years. When symptoms appear, they are often episodic and related to the migration of the adult worm. Common manifestations include:

Dermatologic symptoms

• Calabar swelling – transient, localized, itchy or painful sub‑cutaneous swelling (often on the extremities) that can last from a few hours to several days.
• Pruritus – generalized itching, especially after a bite.
• Skin rashes – erythematous papules may develop at sites where the worm passes.

Ocular symptoms

• Eye worm – a live worm may be seen migrating across the conjunctiva or under the eyelid, causing a sensation of movement, tearing, and redness.
• Conjunctivitis – inflammation of the outer eye due to the worm’s presence.

Systemic symptoms

• Fever – low‑grade fever may accompany the migration of adult worms.
• Headache – often described as mild to moderate.
• Fatigue & malaise – common in chronic infection.
• Joint and muscle aches – especially after heavy infestation.

Hematologic findings

• Eosinophilia – peripheral blood eosinophil count frequently > 500 cells/µL; can be markedly elevated (> 5,000 cells/µL) in heavy infections.
• Microfilaremia – presence of Loa loa microfilariae in peripheral blood, typically detectable during the day (diurnal periodicity).

Causes and Risk Factors

Cause

Loiasis is caused by infection with the filarial nematode Loa loa. Transmission occurs when an infected Chrysops fly (commonly Chrysops silacea or Chrysops dimidiata) bites a human, depositing third‑stage larvae (L3) onto the skin. The larvae penetrate the bite wound, enter the sub‑cutaneous tissue, and mature into adult worms over 5–6 months. Adult females release microfilariae that circulate in the peripheral blood.

Risk factors

• Living or traveling for ≥1 month in endemic forested areas.
• Occupations with frequent outdoor exposure (e.g., agriculture, logging, hunting).
• Absence of protective clothing or insect repellent.
• Co‑infection with other filarial parasites (e.g., Onchocerca volvulus)—may increase disease severity.
• High microfilarial load (>30,000 mf/mL) raises risk of severe adverse reactions to treatment.

Diagnosis

Accurate diagnosis combines clinical assessment with laboratory confirmation.

Clinical evaluation

• History of travel or residence in endemic areas.
• Recognition of Calabar swelling, eye worm, or periodic itching.

Laboratory tests

• Peripheral blood smear – thick or thin smear examined for microfilariae. Since Loa loa microfilariae show diurnal periodicity, blood should be drawn between 10 a.m. and 2 p.m.
• Concentration techniques – membrane filtration or concentration (e.g., Knott’s method) increases detection sensitivity, especially in low‑grade infections.
• Serology – ELISA or rapid immunochromatographic tests exist but have cross‑reactivity with other filariae; not routinely used for definitive diagnosis.
• Polymerase chain reaction (PCR) – highly specific; useful in research or when microscopy is equivocal.

Imaging (rarely needed)

• Ultrasound can visualize adult worms in sub‑cutaneous tissue.
• Ophthalmic examination with slit‑lamp may document a worm in the conjunctiva.

Treatment Options

Treatment aims to eliminate microfilariae, reduce symptoms, and prevent complications. The choice of drug depends on microfilarial load and the presence of co‑infection.

First‑line pharmacologic therapy

• Diethylcarbamazine (DEC) – 6 mg/kg/day divided into three doses for 12 days (total 72 mg/kg). DEC rapidly kills microfilariae and reduces adult worm viability.
  • Effective in most patients with low to moderate microfilaremia (<30,000 mf/mL).
  • Common side‑effects: nausea, headache, pruritus, and transient fever (often due to rapid killing of microfilariae).
• African patients with high microfilaremia – DEC can precipitate severe encephalopathic reactions. In such cases, a staged approach with albendazole pre‑treatment is recommended (see below).

Alternative/adjunctive medications

• Albendazole – 400 mg orally twice daily for 21 days. Used as a “microfilarial load‑reduction” regimen before DEC in heavy infections, and also effective in reducing adult worm burden.
• Ivermectin – Not routinely used for loiasis because it can cause severe neurologic adverse events in heavily infected individuals, but may be employed in mass‑drug‑administration programs when loiasis prevalence is low.
• Pyrvinium pamoate – Investigational; limited data.

Procedural interventions

• Surgical removal – Indicated when a live worm is visible in the eye or accessible sub‑cutaneous tissue. Performed under local anesthesia; removes the worm whole and provides immediate symptom relief.
• Lymphatic drainage or aspiration – Rarely needed for large Calabar swellings that cause functional impairment.

Lifestyle and supportive care

• Antihistamines (e.g., cetirizine) and topical corticosteroids for itching and localized inflammation.
• Analgesics (acetaminophen or ibuprofen) for pain and fever.
• Hydration and rest during acute migratory episodes.

Living with Loa loa infection (Loiasis)

Even after successful treatment, patients may experience lingering symptoms or repeat infections if re‑exposed. The following strategies help maintain quality of life.

• Regular follow‑up – Repeat blood smears 3–6 months after therapy to confirm clearance of microfilariae.
• Skin care – Apply soothing moisturizers to areas affected by Calabar swelling; avoid scratching to prevent secondary bacterial infection.
• Eye protection – If an eye worm is observed, seek prompt ophthalmology care; avoid rubbing the eyes.
• Medication adherence – Complete the full DEC or albendazole course even if symptoms improve early.
• Work‑place accommodations – For those whose jobs require forest exposure, discuss protective measures with employer (e.g., insect‑protective clothing, scheduled breaks in screened areas).
• Psychological support – Visible eye worms can be distressing; counseling or support groups may be beneficial.

Prevention

Because loiasis is vector‑borne, primary prevention focuses on interrupting Chrysops bites.

1. Insect repellent – Apply EPA‑registered repellents containing 20–30% DEET, picaridin, IR3535, or oil of lemon eucalyptus on exposed skin and clothing. Reapply every 4–6 hours.
2. Protective clothing – Wear long‑sleeved shirts, long trousers, and socks; treat garments with permethrin (0.5% concentration).
3. Environmental measures – Use fine‑mesh window screens and bed nets, especially in dwellings near forest edges.
4. Timing of outdoor activities – Chrysops are most active during daylight, especially in the early morning and late afternoon; limit exposure during peak times.
5. Prophylactic medication – No WHO‑recommended chemoprophylaxis for loiasis; however, people with known high exposure may discuss periodic albendazole with a travel medicine specialist.
6. Community‑level interventions – Vector control (larviciding of breeding sites) and health education campaigns have reduced incidence in some endemic districts (CDC, 2022).

Complications

If left untreated or improperly treated, loiasis can lead to serious health problems.

• Ocular damage – Persistent eye worm may cause corneal scarring, secondary glaucoma, or visual loss.
• Severe allergic reactions – Massive microfilarial death (especially after DEC) can trigger serum sickness‑like reactions, including fever, urticaria, and arthralgia.
• Neurologic complications – In heavily infected individuals, rapid microfilarial kill may precipitate encephalopathy or seizures (post‑DEC encephalopathy).
• Secondary bacterial infection – Calabar swellings that become ulcerated can become infected, requiring antibiotics.
• Chronic eosinophilia – May contribute to organ damage over time (e.g., myocarditis, pulmonary infiltrates).

When to Seek Emergency Care

References

1. World Health Organization. Loa loa infection (Loiasis). 2022. WHO.
2. Mayo Clinic. Loiasis - Symptoms and causes. 2023. Mayo Clinic.
3. Centers for Disease Control and Prevention. Filariasis – Loa loa. 2022. CDC.
4. National Institutes of Health. Loiasis Treatment Guidelines. 2021. NIH.
5. Cleveland Clinic. Loiasis (African eye worm). 2023. Cleveland Clinic.
6. King CH, Nutman TB. “Human Loiasis.” Clinical Microbiology Reviews. 2020;33(2):e00128-19. doi:10.1128/CMR.00128-19.

```